ADMA Biologics Inc vs Workday Inc — how do they compare? ADMA Biologics Inc trades at $9.91 (market cap $2.22B), while Workday Inc trades at $174.2 (market cap $44.77B). The key difference: Workday Inc is far larger — about 20.2× ADMA Biologics Inc's market cap, and Workday Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | WDAY | |
|---|---|---|
Market Cap | $2.22B | $44.77B |
Sector | Health | Technology |
52-Week High | $20.38 | $247.69 |
52-Week Low | $7.60 | $112.55 |
Enterprise Value | $2.29B | $44.22B |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
Workday (WDAY) trades at $184.19, up 2.53% with strong technical momentum and consecutive earnings beats. The stock shows bullish moving average signals despite overbought RSI readings. Revenue growth accelerated to $8.45 billion in 2025 with improving net margins of 6.22%, while analyst consensus remains positive with 55.6% buy ratings. Recent partnerships and AI product launches demonstrate continued innovation in enterprise software.
Outlook remains constructive given consistent earnings outperformance and AI-driven growth initiatives, though elevated valuation multiples and institutional selling present near-term headwinds. Key risks include competitive pressures and execution challenges in enterprise software market transitions.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Workday is a software company that offers human capital management, or HCM, financial management, and business planning solutions. Known for being a cloud-only software provider, Workday is headquartered in Pleasanton, California. Founded in 2005, Workday now employs over 12,000 employees.
Read more on WDAY →